Frontiers in Cancer ResearchNova Publishers, 2006 - 256 páginas Cancer is a group of different diseases (over 100) characterised by uncontrolled growth and spread of abnormal cells. Cancer can arise in many sites and behave differently depending on its organ of origin. If a cancer spreads (metastasises), the new tumour bears the same name as the original (primary) tumour. Significant progress has been made in recent years in the battle against cancer and in understanding its underlying biological mechanisms. This research progress has resulted in many experimental treatments and cures which establish hope for wide-spread cures. This book brings together important research from around the world in this frontal field. |
Índice
| xi | |
Craniomaxillofacial Resection for Advanced Oral and Maxillofacial Tumors | 51 |
FasResistance in Adult TCell Leukemia Lymphoma | 81 |
Cranial Prophylaxis in NonHodgkins Lymphoma | 111 |
Clinical Significance of PGlycoprotein in Acute Leukemia and a Strategy to Overcome Drug Resistance | 121 |
Quality of Life of Metastatic Renal Carcinoma Patients Receiving Subcutaneous Interferon or Intravenous Interleukin2 | 151 |
Control of BCLL Apoptosis by Members of the TNF Superfamily | 167 |
Surgical Management of Advanced Primary and Recurrent Ovarian Cancer The Washington Cancer Institute Approach | 209 |
The Clinical Value of Static DNA Cytometry in the Diagnosis Prognosis and Therapy of Prostate and Bladder Cancer | 229 |
Index | 241 |
Términos y frases comunes
abnormalities activation acute leukemia acute lymphoblastic leukemia acute myeloid leukemia adult T-cell analysis antibody antigen antisense apoptosis ATLL cells autocrine B-CLL cells B-CLL patients BAFF and APRIL bladder bone marrow carcinoma caspase cell lines chronic lymphocytic leukemia Clin clinical correlation craniofacial resection craniomaxillofacial resection cytogenetic cytokines cytoreduction detected diagnosis differentiation drug EGIL evaluation flap flow cytometry foramen gene Haematol HLA-DR immunophenotype immunophenotypic profile induced inhibits interleukin-2 intracellular intraperitoneal chemotherapy involvement Leuk leukemic blast cells leukemic cells levels ligand lineage lymphoid malignant markers mdr1 MDR1-AS mFas middle cranial fossa minimal residual disease molecules mRNA multidrug resistance non-Hodgkin's lymphoma normal oligonucleotides Oncol ovarian cancer P-gp expression P-gp positive peritoneal phenotype proliferation protein receptor relapse reported sensitivity serum sFas significantly skull base soluble subtypes surgery surgical survival survivin T-ALL T-cell leukemia therapy tissues TNF-a treatment tumor necrosis factor vitro